This insider sale cluster is too small to be informative, monitor for larger insider activity or upcoming catalysts like clinical trial data readouts. The company's strong analyst consensus (92% bullish) and prior insider buying patterns (multiple signal_insider_buy events in July 2026) suggest this selling is likely liquidity-driven rather than signaling fundamental concerns.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 8 $10.88entry
- T+1 · 2mo ago −0.83%α −0.36% · $10.79
- T+5 · 2mo ago −18.11%α −16.99% · $8.91
- T+20 · 6w ago −33.18%α −35.15% · $7.27
- T+49 · todayOpen
- T+60 · in 15d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite insiders at Artiva Biotherapeutics (COO/CLO and CMO) sold a combined $192K in open-market sales over a 7-day window. The total value represents just 0.035% of the company's $544M market cap, making this a routine and immaterial cluster of insider sales with no predictive signal.
Key Financial Metrics
Key Facts
- COO/CLO Jennifer Bush sold 8,391 shares at $11.16 for $94K on 2026-09-03
- CMO Subhashis Banerjee sold 8,200 shares at $12.01 for $99K on 2026-08-27
- Total insider sales of $192K represent only 0.035% of ARTV's $544M market cap
- Both sales were open-market transactions (code S), not tax-withholding or exercise-related
Financial Impact
Total insider sales of $192K, representing 0.035% of market cap, immaterial
Risk Factors
- Insider selling could accelerate if clinical trial results disappoint
- Biotech sector binary risk around pipeline milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1788588440257 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers